EIF2AK2 Mouse monoclonal Antibody IgG1

SKU: BA112732-100µl
$279.00Price

Fig1: Western blot analysis of EIF2AK2 on human EIF2AK2 recombinant protein using anti- EIF2AK2 antibody at 1/1,000 dilution.

Fig2: Western blot analysis of EIF2AK2 on HEK293 (1) and EIF2AK2-hIgGFc transfected HEK293 (2) cell lysateusing using anti-FTL antibody at 1/1,000 dilution.

Fig3: Western blot analysis of EIF2AK2 on  cells lysates using anti- EIF2AK2 antibody at 1/1,000 dilution.

Positive control: Line1: A431           Line2:  THP-1  Line3: MCF-7          Line4: PC-12

Bon Opus Cat. #BA112732
Size
  • Host Species; Species Reactivity

    Mouse; Human
  • Immunogen

    Recombinant protein
  • Application Summary

    WB, IHC, FC
  • Purification; Formulation

    ProA affinity purified; 1*TBS (pH7.4), 1%BSA, Preservative: 0.05% Sodium Azide.; Liquid form.
  • ALTnames

    Casein kinase II subunit beta, Phosvitin, Protein G5a
  • Background

    Interferon-inducible RNA-dependent protein serine/threonine kinase, PKR, is variously designated in earlier literature as DAI, dsJ, PI kinase, p65, p67 or TIK for the mouse kinase; and p68, eIF-2α protein kinase or p69 for the human kinase. The PKR kinase substrate is the α subunit of protein synthesis initiation factor eIF-2. Phosphorylation of eIF-2α on serine-51 results in inhibition of translation. Molecular cDNA clones have been isolated from both human and mouse cells. The serine/threonine kinase catalytic domains map to the carboxy terminal half of the protein while the RNA-binding domains are located in the amino terminal region. Three kinds of regulation of PKR enzymatic activity have been described. These include transcriptional regulation in response to interferon, an autoregulatory mechanism controlling PKR expression at the level of translation and post-translational regulation by RNA-mediated autophosphorylation.(EM1706-35)

(800) 943-6396

150 Essex St, Millburn, NJ 07041, USA

©2020 by Bon Opus Biosciences, LLC.